Lactoferricin, Bovine, mAb 5F12.1.2
Monoclonal antibody clone 5F12.1.2, anti bovine Lactoferricin B is highly specific for bovine Lactoferricin B. This peptide is derived by enzymatic cleavage of lactoferrin which is a member of the transferrin family of metal-binding proteins found in milk and other secretory fluids and also in blood. Cleavage by pepsin of bovine lactoferrin leads to the release of Lactoferricin B (aminoacid 17-41). This peptide is highly basic, possessing five Arg (R) and three Lys (K) residues. In addition, a number of Trp (W) and Phe (F) aromatic residues are present. The two Cys (C) residues from lactoferricin B form a disulfide bond, generating an almost completely cyclical peptide. Nevertheless, the disulfide bond is not required for the antimicrobial potency. Several studies have shown that Lactoferricin B has a broad-spectrum activity against various Gram-positive and Gram-negative bacteria. In addition the peptide has been shown to have antifungal, antiviral and antitumour activity and to bind lipopolysaccharides (LPS, endotoxin). Moreover, it is known to stimulate the adaptive immune response and has anti-inflammatory properties. Lactoferricin B belongs to a large group of cationic antimicrobial peptides. The monoclonal antibody 5F12.1.2 is specific for bovine Lactoferricin B and detects the QWR antigenic determinant specific for bovine Lactoferricin B (3kDa), it lacks reactivity with bovine lactoferrin C-lobe, human lactoferrin or lactoferricin H. The QWR sequence recognized by the antibody 5F12.1.2 is not present in lactoferrin in human, pig, mouse, goat, rabbit, horse, rat, cockroach and African clawed frog.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis